Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) saw unusually-strong trading volume on Friday . Approximately 3,554 shares traded hands during mid-day trading, an increase of 380% from the previous session’s volume of 741 shares.The stock last traded at $321.05 and had previously closed at $310.00.
Analysts Set New Price Targets
Several research analysts recently issued reports on UCBJF shares. Wolfe Research started coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday, February 16th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy”.
View Our Latest Stock Report on UCBJF
UCB Stock Performance
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Recommended Stories
- Five stocks we like better than UCB
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
